Aprea Therapeutics, Inc.

NASDAQ: APRE · Healthcare · Biotechnology

PublicHQ Boston, MA · SuffolkCIK 0001781983Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 43DQ —GM —SS 34

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, filing timeliness · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

-100.0%

Net income (FY)

-$12.6M

Employees

as of 2026-09-21

Market cap

$9.2M

as of 2026-09-21

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$12.6M-$12.6M2025

Operating income-$13.2M-$13.2M2025

Total assets$15.9M$15.9M2025

Liabilities$3.2M$3.2M2022

Equity$12.4M$12.4M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Aprea Therapeutics, Inc.’s financial profile?

Aprea Therapeutics, Inc. earned -$12.6M in FY2025 net income.

Peers · Healthcare

IN8bio, Inc.——Brainstorm Cell Therapeutics Inc.——Conavi Medical Corp.——Advanced Biomed Inc. Common Stock——Quince Therapeutics, Inc.——Skye Bioscience, Inc.——

Neighbors

Suffolk →

Vertex Pharmaceuticals Incorporated$12.0B88A American Tower Corporation$935.9M76B+State Street Corporation$13.9B67B NSTAR Electric Company——Toast, Inc.$6.2B67B PTC Inc.$2.7B83B+

Key facts

CEOOren Gilad

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, MA

ExchangeNASDAQ: APRE

Employees8

IPO date2019-10-03

Latest filings

8-K2026-08-28 10-Q2026-08-12 8-K2026-08-12 8-K2026-07-23 8-K2026-06-17 8-K2026-05-13 10-Q2026-05-13 DEF 14A2026-04-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.